drugset
drugset / Trial / NCT06696261

A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

NCT06696261 ↗

Phase 3 Recruiting 342 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are: 1. Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo. 2. Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome. 3. Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.

Timeline

Start
2025-02-27
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lianxiaxiaopi Granules Unknown 1 unknown Oral

Indications

No indication recorded.